Comparison of clinical and laboratory parameters in patients with migraine or tension-type headaches: A case-control study

Year 2021, Volume: 5 Issue: 8, 777 - 779, 01.08.2021

Murat Yılmaz , Handan Teker , Tahsin Bakkal Aysen Tugba Canbasoglu Yılmaz Sule Aydın Türkoğlu , Serpil Kuyucu

https://doi.org/10.28982/josam.948316

Abstract

Background/Aim: Migraine and tension-type headaches (TTH) are common headache disorders that are not caused by or attributed to another disorder, and it is important to elucidate the clinical and laboratory features in patients with these diseases. This study aimed to compare the clinical and laboratory features of migraine patients with TTH.
Methods: Nineteen patients with TTH, 73 patients with migraine, and 30 volunteers without headache who visited Bolu Abant Izzet Baysal Training and Research Hospital between January 2018 and December 2018 were included in this case-control study. Patients’ Fazekas score, age, gender, muscle score, hemogram parameters, parathyroid hormone, protein C, Protein S, Antithrombin III, low-density lipoprotein cholesterol, vitamin D, folate, vitamin B12 levels, antiphospholipid, anticardiolipin, thyroid autoantibodies, and ANA positivity were noted.
Results: The mean age in the migraine, TTH, and control groups were 43.54 (11.60), 47.05 (12.09), and 47.23 (12.33) years, respectively (P=0.261). There was no difference between the groups in terms of gender distribution (P=0.115). The Fazekas scores of the migraine (1[0-3]) and TTH groups (1[0-3]) were higher than controls (0[0-2]) (P<0.001).
Conclusion: Considering the Fazekas scores and antithrombin III levels in clinical and laboratory evaluation will be useful in the diagnosis and differentiation of migraine and TTH.

Keywords

Hormones, Migraine, Tension-type headache

References

• 1. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurologic Clinics. 2019;37(4):631-49. doi: 10.1016/j.ncl.2019.06.001.
• 2. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA. 1998;279(5):381-3. doi: 10.1001/jama.279.5.381.
• 3. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018;17(11):954-76. doi: 10.1016/s1474-4422(18)30322-3.
• 4. Evans RW. Diagnostic Testing for Migraine and Other Primary Headaches. Neurologic Clinics. 2019;37(4):707-25. doi: 10.1016/j.ncl.2019.08.001.
• 5. Burch R. Migraine and Tension-Type Headache: Diagnosis and Treatment. Medical Clinics of North America. 2019;103(2):215-33. doi: 10.1016/j.mcna.2018.10.003.
• 6. Riesco N, Cernuda-Morollón E, Pascual J. Neuropeptides as a Marker for Chronic Headache. Curr Pain Headache Rep. 2017;21(4):18. doi: 10.1007/s11916-017-0618-8.
• 7. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR: American Journal of Roentgenology. 1987;149(2):351-6. doi: 10.2214/ajr.149.2.351.
• 8. Sarıcam G. Relationship between migraine headache and hematological parameters. Acta Neurologica Belgica. 2020. doi: 10.1007/s13760-020-01362-x.
• 9. Rudilosso S, San Román L, Blasco J, Hernández-Pérez M, Urra X, Chamorro Á. Evaluation of white matter hypodensities on computed tomography in stroke patients using the Fazekas score. Clinical Imaging. 2017;46:24-7. doi: 10.1016/j.clinimag.2017.06.011.
• 10. Kruit MC, Van Buchem MA, Hofman PA, Bakkers JT, Terwindt GM, Ferrari MD, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004;291(4):427-34. doi: 10.1001/jama.291.4.427.
• 11. Palm-Meinders IH, Koppen H, Terwindt GM, Launer LJ, Konishi J, Moonen JM, et al. Structural brain changes in migraine. JAMA. 2012;308(18):1889-97. doi: 10.1001/jama.2012.14276.
• 12. Hamedani AG, Rose KM, Peterlin BL, Mosley TH, Coker LH, Jack CR, et al. Migraine and white matter hyperintensities: the ARIC MRI study. Neurology. 2013;81(15):1308-13. doi: 10.1212/WNL.0b013e3182a8235b.
• 13. Kurth T, Mohamed S, Maillard P, Zhu YC, Chabriat H, Mazoyer B, et al. Headache, migraine, and structural brain lesions and function: population based Epidemiology of Vascular Ageing-MRI study. BMJ. 2011;342:c7357. doi: 10.1136/bmj.c7357.
• 14. Honningsvåg LM, Håberg AK, Hagen K, Kvistad KA, Stovner LJ, Linde M. White matter hyperintensities and headache: A population-based imaging study (HUNT MRI). Cephalalgia. 2018;38(13):1927-39. doi: 10.1177/0333102418764891.
• 15. Ulusoy EK. Use of MPV and MPV/Plt Ratio in the Differentiation of Migraine and Tension-Type Headache. Acta Haematologica Polonica. 2018;49(1):15-9.
• 16. Sarchielli P, Alberti A, Coppola F, Baldi A, Gallai B, Floridi A, et al. Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks. Cephalalgia. 2004;24(8):623-30. doi: 10.1111/j.1468-2982.2003.00717.x.
• 17. Jernej B, Vladić A, Cicin-Sain L, Hranilović D, Banović M, Balija M, et al. Platelet serotonin measures in migraine. Headache. 2002;42(7):588-95. doi: 10.1046/j.1526-4610.2002.02145.x.
• 18. Findakly D, Komro J. Not Just Another Headache: Cerebral Venous Sinus Thrombosis in a Patient With Isolated Antithrombin III Deficiency. Cureus. 2020;12(5):e8383. doi: 10.7759/cureus.8383.
• 19. Mehta A, Danesh J, Kuruvilla D. Cerebral Venous Thrombosis Headache. Curr Pain Headache Rep. 2019;23(7):47. doi: 10.1007/s11916-019-0786-9.